GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billion
GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includes an upfront payment of $1.2 billion and milestone payments. Efimosfermin, targeting steatotic liver disease and MASH, is expected to launch in 2029, with (...)
Site référencé: The Economic Times
The Economic Times
2 top stock recommendations from Aamar Deo Singh
1er/05/2025
Crypto industry descends on Dubai as Trump euphoria recedes
1er/05/2025
ETMarkets Smart Talk | India-Pak tensions seen as temporary ; focus on earnings, Gold allocation up to 20% : Vikram Kasat
1er/05/2025
Eternal to announce Q4 results today : Profit to take severe hit even as revenue growth seen strong
1er/05/2025
